The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMTX | +39.66% | +3.31% | +0.65% | +10% |
| S&P | +12.33% | +84.73% | +13.06% | +153% |
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.
Investors liked the company's latest clinical update.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.06M | -89.1% |
| Market Cap | $1.04B | -11.9% |
| Market Cap / Employee | $2.45M | 0.0% |
| Employees | 423 | 23.3% |
| Net Income | -$59.06M | -527.4% |
| EBITDA | -$60.29M | -1654.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $393.53M | 86.4% |
| Accounts Receivable | $3.76M | 14.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.86M | 7.7% |
| Short Term Debt | $3.38M | -82.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.21% | -10.3% |
| Return On Invested Capital | -109.34% | -15.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$56.16M | -34.2% |
| Operating Free Cash Flow | -$54.74M | -42.2% |
| Metric | Q4 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 88.21 | - | |||
| Price to Book | 1.72 | 0.92 | 1.13 | 1.90 | -32.89% |
| Price to Sales | 5.13 | 3.53 | 4.66 | 11.38 | 21.62% |
| Price to Tangible Book Value | 1.72 | 0.92 | 1.13 | 1.91 | -32.94% |
| Enterprise Value to EBITDA | 60.89 | 0.56 | -1.98 | -9.10 | -105.32% |
| Return on Equity | 3.7% | -4.5% | -17.3% | -29.0% | 65.94% |
| Total Debt | $18.57M | $20.01M | $20.09M | $19.25M | -43.99% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
